阿米卡星联合头孢哌酮钠舒巴坦钠治疗重症肺炎患者的效果  

Effects of Amikacin combined with Cefoperazone sodium and Sulbactam sodium in treatment of patients with severe pneumonia

作　　者：田歌 李婵 TIAN Ge;LI Chan(Department of Western Medicine of Nanyang First People’s Hospital,Nanyang 473000 Henan,China;Pharmaceutical Department of Xinye County People’s Hospital,Nanyang 473000 Henan,China)

机构地区：[1]南阳市第一人民医院西药科,河南南阳473000 [2]新野县人民医院药剂科,河南南阳473000

出　　处：《中国民康医学》2025年第8期41-43,47,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察阿米卡星联合头孢哌酮钠舒巴坦钠治疗重症肺炎患者的效果。方法:回顾性分析2021—2022年南阳市第一人民医院收治的82例重症肺炎患者的临床资料,按照治疗方法不同将其分为对照组与观察组各41例。对照组给予头孢哌酮钠舒巴坦钠治疗,观察组在对照组基础上联合阿米卡星治疗。比较两组临床疗效,治疗前后血清炎性指标[C反应蛋白(CRP)、降钙素原(PCT)、白细胞计数(WBC)]、肺通气功能指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))、动脉血氧饱和度(SaO_(2))]水平,以及不良反应发生率。结果:观察组治疗总有效率为90.24%(37/41),高于对照组的73.17%(30/41),差异有统计学意义(P<0.05);治疗后,两组CRP、PCT、WBC水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组PaO_(2)、SaO_(2)水平均高于治疗前,且观察组高于对照组,两组PaCO_(2)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿米卡星联合头孢哌酮钠舒巴坦钠治疗重症肺炎患者可提高治疗总有效率,改善肺通气功能指标水平,降低血清炎性指标水平,效果优于单纯头孢哌酮钠舒巴坦钠治疗。Objective:To observe effect of Amikacin combined with Cefoperazone sodium and Sulbactam sodium in treatment of patients with severe pneumonia.Methods:The clinical data of 82 patients with severe pneumonia admitted to Nanyang First People’s Hospital from 2021 to 2022 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,41 cases in each group.The control group was treated with Cefoperazone sodium and Sulbactam sodium,while the observation group was treated with Amikacin on the basis of that of the control group.The clinical efficacies,the levels of serum inflammatory indexes[C-reactive protein(CRP),procalcitonin(PCT),white blood cell count(WBC)],pulmonary ventilation function indexes[arterial partial pressure of oxygen(PaO_(2)),arterial partial pressure of carbon dioxide(PaCO_(2)),arterial oxygen saturation(SaO_(2))]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 90.24%(37/41),which was higher than 73.17%(30/41)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CRP,PCT and WBC in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of PaO_(2) and SaO_(2) in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;the PaCO_(2) levels of the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Amikacin combined with Cefoperazone sodium and Sulbactam sodium in t

关 键 词：重症肺炎 头孢哌酮钠舒巴坦钠 阿米卡星 肺通气功能 不良反应 

分 类 号：R563.1[医药卫生—呼吸系统]